In a report released yesterday, Sam Eiber from BTIG reiterated a Buy rating on Evolus (EOLS – Research Report), with a price target of $21.00.
Sam Eiber has given his Buy rating due to a combination of factors that highlight Evolus’s potential for growth and market share expansion. Despite a slight miss in the top-line revenue for the first quarter, Evolus maintained its full-year revenue guidance, indicating confidence in its ability to accelerate share gains in the toxin market. The company’s new product, Evolysse, is showing promising early results, surpassing the initial launch performance of Jeuveau, which is a positive indicator for future revenue contributions.
Additionally, Evolus has demonstrated strong customer engagement, with a significant increase in new accounts and a high reorder rate for Jeuveau. The expansion of the Evolus Rewards loyalty program further supports customer retention and growth. The company’s long-term targets, including substantial revenue growth and improved operating income margins by 2028, reinforce the positive outlook. These factors collectively contribute to the Buy rating, as they represent potential upside opportunities for Evolus in a challenging market environment.
In another report released today, Mizuho Securities also maintained a Buy rating on the stock with a $25.00 price target.
EOLS’s price has also changed moderately for the past six months – from $14.290 to $11.760, which is a -17.70% drop .